Induction of p53 and p21 proteins by gamma radiation in skin fibroblasts derived from breast cancer patients

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 2, 2004, Pages 479-484

  Torres, Martha ^a   Al Buhairi, Muneera ^a   Alsbeih, Ghazi ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Ataxia telangiectasia; Ataxia telangiectasia heterozygous; Breast cancer susceptibility; CDKN1A (p21); TP53 (p53)

Indexed keywords

GENETIC ENGINEERING; IONIZING RADIATION; IRRADIATION; PROTEINS; TUMORS;

FIBROBLASTS;

ONCOLOGY;

PROTEIN P21; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

ATAXIA TELANGIECTASIA; BIOACCUMULATION; BREAST CANCER; CANCER PATIENT; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; GAMMA RADIATION; GENETIC STABILITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; RADIATION EXPOSURE; SKIN FIBROBLAST; STATISTICAL ANALYSIS; WESTERN BLOTTING;

EID: 0942278940     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.062     Document Type: Conference Paper

References (45)

1. Giaccia A.J., Kastan M.B. The complexity of p53 modulation Emerging patterns from divergent signals . Genes Dev. 12:1998;2973-2983.
2. Ko L.J., Prives C. p53 Puzzle and paradigm . Genes Dev. 10:1996;1054-1072.
3. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
4. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1990;1233-1238.
5. Santibanez-Koref M.F., Birch J.M., Hartley A.L., et al. p53 germline mutations in Li-Fraumeni syndrome. Lancet. 338:1991;1490-1491.
6. Potzsch C., Voigtlander T., Lubbert M. p53 germline mutation in a patient with Li-Fraumeni syndrome and three metachronous malignancies. J Cancer Res Clin Oncol. 128:2002;456-460.
7. Hirao A., Kong Y.Y., Matsuoka S., et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 287:2000;1824-1827.
8. Bell D.W., Varley J.M., Szydlo T.E., et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 286:1999;2528-2531.
9. Lee S.B., Kim S.H., Bell D.W., et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res. 61:2001;8062-8067.
10. Meijers-Heijboer H., van den Ouweland A., Klijn J., et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 31:2002;55-59.
11. Vahteristo P., Bartkova J., Eerola H., et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 71:2002;432-438.
12. Easton DF. Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994;66:S177-S182.
13. Spring K., Ahangari F., Scott S.P., et al. Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer. Nat Genet. 32:2002;185-190.
14. Angele S., Hall J. The ATM gene and breast cancer Is it really a risk factor? Mutat Res. 462:2000;167-178.
15. Angele S., Treilleux I., Taniere P., et al. Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas. Clin Cancer Res. 6:2000;3536-3544.
16. Jongmans W., Hall J. Cellular responses to radiation and risk of breast cancer. Eur J Cancer. 35:1999;540-548.
17. Khosravi R., Maya R., Gottlieb T., et al. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A. 96:1999;14973-14977.
18. Nasrin N., Kunhi M., Einspenner M., et al. Reduced induction of P53 protein by gamma-irradiation in ataxia telangiectasia cells without constitutional mutations in exons 5, 6, 7, and 8 of the p53 gene. Cancer Genet Cytogenet. 77:1994;14-18.
19. Kastan M.B., Zhan Q., el-Deiry W.S., et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia- telangiectasia. Cell. 71:1992;587-597.
20. Canman C.E., Wolff A.C., Chen C.Y., et al. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res. 54:1994;5054-5058.
21. Birrell G.W., Ramsay J.R. Induction of p53 protein by gamma radiation in lymphocyte lines from breast cancer and ataxia telangiectasia patients. Br J Cancer. 72:1995;1096-1101.
22. Nasrin N., Mimish L.A., Manogaran P.S., et al. Cellular radiosensitivity, radioresistant DNA synthesis, and defect in radioinduction of p53 in fibroblasts from atherosclerosis patients. Arterioscler Thromb Vasc Biol. 17:1997;947-953.
23. Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: Defects in chromosome instability syndromes? 1993;75:765-778.
24. Rosselli F., Ridet A., Soussi T., et al. p53-dependent pathway of radio-induced apoptosis is altered in Fanconi anemia. Oncogene. 10:1995;9-17.
25. Antoccia A., Stumm M., Saar K., et al. Impaired p53-mediated DNA damage response, cell-cycle disturbance and chromosome aberrations in Nijmegen breakage syndrome lymphoblastoid cell lines. Int J Radiat Biol. 75:1999;583-591.
26. Little J.B., Nagasawa H., Dahlberg W.K., et al. Differing responses of Nijmegen breakage syndrome and ataxia telangiectasia cells to ionizing radiation. Radiat Res. 158:2002;319-326.
27. Nathanson K.L., Wooster R., Weber B.L., et al. Breast cancer genetics What we know and what we need . Nat Med. 7:2001;552-556.
28. Foray N., Randrianarison V., Marot D., et al. Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2. Oncogene. 18:1999;7334-7342.
29. Patel K.J., Yu V.P., Lee H., et al. Involvement of Brca2 in DNA repair. Mol Cell. 1:1998;347-357.
30. Mueller C.R., Roskelley C.D. Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res. 5:2002;45-52.
31. Alsbeih G., Malone S., Lochrin C., et al. Correlation between normal tissue complications and in vitro radiosensitivity of skin fibroblasts derived from radiotherapy patients treated for variety of tumors. Int J Radiat Oncol Biol Phys. 46:2000;143-152.
32. Di Leonardo A., Linke S.P., Clarkin K., et al. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8:1994;2540-2551.
33. Itahana K., Dimri G.P., Hara E., et al. A role for p53 in maintaining and establishing the quiescence growth arrest in human cells. J Biol Chem. 277:2002;18206-18214.
34. Savitsky K., Bar-Shira A., Gilad S., et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 268:1995;1749-1753.
35. Gilad S, Khosravi R, Shkedy D, et al. Predominance of null mutations in ataxia-telangiectasia. Hum Mol Genet 1996;5:433-439.
36. Scott S.P., Bendix R., Chen P., et al. Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci U S A. 99:2002;925-930.
37. Lim D.S., Kim S.T., Xu B., et al. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature. 404:2000;613-617.
38. Chenevix-Trench G., Spurdle A.B., Gatei M., et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 94:2002;205-215.
39. Scully R., Chen J., Ochs R.L., et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell. 90:1997;425-435.
40. Cortez D., Wang Y., Qin J., et al. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science. 286:1999;1162-1166.
41. Somasundaram K. Breast cancer gene 1 (BRCA1) Role in cell cycle regulation and DNA repair-perhaps through transcription . J Cell Biochem. 88:2003;1084-1091.
42. Somasundaram K., Zhang H., Zeng Y.X., et al. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature. 389:1997;187-190.
43. Zhang H., Somasundaram K., Peng Y., et al. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene. 16:1998;1713-1721.
44. Marmorstein L.Y., Ouchi T., Aaronson S.A. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci U S A. 95:1998;13869-13874.
45. Wilson J.H., Elledge S.J. Cancer. BRCA2 enters the fray. Science. 297:2002;1822-1823.